Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Recent News
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Nutra Pharma Engages HealthForce LLC for Sales, Marketing and Distribution of Designer Diagnostics' Test Kits
March 21, 2006

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that Designer Diagnostics has engaged HealthForce LLC to sell, market, and distribute its diagnostic test kits. Designer Diagnostics is a wholly owned subsidiary of Nutra Pharma.

The management of HealthForce LLC has a strong background in hospital administration and medical device distribution. Steve Wilson, managing partner of HealthForce LLC, has over 30 years of experience in the medical industry, sales and administration. Mr. Wilson has a Masters of Public Health, has run some of the largest hospital facilities in the United States and has a complete understanding of the logistics of the medical industry. His partner, Dennis D. Solheim, has 30 years of healthcare experience that encompasses physician partnerships in ambulatory surgery facilities and hospitals. Dennis graduated from Iowa State University in 1974. He has been a founder of two successful start up companies, National Surgery Centers and National Specialty Hospitals founded in 1999. Dennis has been the Chief Development Officer of National Specialty Hospitals with responsibility for acquisitions and development of new projects. Steve and Dennis bring a wealth of experience in developing and implementing marketing and growth strategies.

Designer Diagnostics owns or has the rights to 29 issued patents related to the rapid isolation, growth, identification and antibiotic sensitivity testing of disease causing pathogens such as Tuberculosis ("TB") and Mycobacterium avium-intracellulare ("MAI"). These patents were used for the production of the Designer Diagnostics TestKit. The basic test kit consists of a glass slide coated with paraffin, which is used as a carbon (food) source or growth surface by certain pathogenic bacterial species. The slides are incubated in a sample of almost any bodily fluid (a non-invasive sample of saliva is preferred) within a nutrient broth. This creates a semi-solid growth medium for the bacteria, which imitates its natural environment within a human or animal host. The bacteria collect on the paraffin slide in 4-8 days. Testing can then be done to identify the species of bacteria. This testing can be done via acid-fast staining or through PCR gene amplification. Additionally, the bacteria can be cultured with antibiotics to test for specific sensitivities. Through the choice of different nutrient broths, each kit can be tailored to encourage the growth of a specific bacterium. The test kits are being designed to work on a class of bacteria that includes TB, MAI, Para-tuberculosis, Pseudomonas and Nocardia.

"Designer Diagnostics has a great product that we believe will quickly gain market leadership. We plan to immediately begin implementing our five-year business plan," commented Steve Wilson, Managing Partner of HealthForce LLC. "We expect to begin generating revenues and profits through the sale of the diagnostic kits in the second quarter of 2006."

In addition to its sales and marketing roles, HealthForce LLC will oversee the FDA approval process of the diagnostic test kits. After approval, HealthForce LLC will be responsible for sales, marketing and distribution of the kits throughout the United States and the European Union.

"We are very excited about the talent and experience that HealthForce brings to Nutra Pharma and Designer Diagnostics," said Neil Roth, President of Designer Diagnostics. "Their proven track record and level of knowledge will lend to our future growth and success," he added.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Engaging HealthForce LLC for sales, marketing and distribution of the Designer Diagnostics' Test Kits should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy

June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet

June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics